At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Nov 12, 2026 at 16:01 ET
MacroGenics reported Q3 2026 revenue of $18.7M, well below the $39.2M consensus, and a GAAP net loss of $20.1M (EPS -$0.32) vs. consensus EPS of -$0.13. The revenue miss was driven by the absence of large milestone payments that boosted the prior-year quarter. The company ended the quarter with $287.7M in cash, extending its runway through 2028, and highlighted pipeline progress with MGC028, MGC026, and lorigerlimab.
- Total revenue of $18.7M for Q3 2026, down 64.8% from $53.0M in Q3 2025, missing the $39.2M consensus.
- GAAP net loss of $20.1M (EPS -$0.32) vs. net income of $16.8M in Q3 2025; consensus EPS was -$0.13.
- Cash, cash equivalents and marketable securities of $287.7M as of September 30, 2026, up from $189.9M at year-end 2025; cash runway guidance through 2028.
- Received $119.6M from sale of GMP manufacturing operations to Bora, $24.5M regulatory milestone from Sanofi, and $10.0M option license payment from Gilead during Q3.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access